• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Co-Chief Executive Officer Talasaz Amirali sold $5,936,572 worth of shares (120,716 units at $49.18), decreasing direct ownership by 5% to 2,188,740 units (SEC Form 4)

    5/5/25 9:02:01 PM ET
    $GH
    Medical Specialities
    Health Care
    Get the next $GH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Talasaz AmirAli

    (Last) (First) (Middle)
    3100 HANOVER STREET

    (Street)
    PALO ALTO CA 94304

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Guardant Health, Inc. [ GH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Co-Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/01/2025 S 18,069(1) D $47.6659(2) 2,291,387 D
    Common Stock 05/01/2025 S 38,477(1) D $48.7122(3) 2,252,910 D
    Common Stock 05/01/2025 S 44,691(1) D $49.5337(4) 2,208,219 D
    Common Stock 05/01/2025 S 3,445(1) D $50.9128(5) 2,204,774 D
    Common Stock 05/01/2025 S 1,748(1) D $51.5622(6) 2,203,026 D
    Common Stock 05/01/2025 S 354(1) D $52.5729(7) 2,202,672 D
    Common Stock 05/02/2025 S 13,932(1) D $50.4702(8) 2,188,740 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024.
    2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.18 to $48.175 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.185 to $49.16 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.19 to $50.06 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.405 to $51.34 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    6. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.43 to $51.76 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    7. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.46 to $52.75 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    8. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.84 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    Remarks:
    /s/ John G. Saia, as attorney-in-fact for AmirAli Talasaz 05/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GH

    DatePrice TargetRatingAnalyst
    4/10/2025$55.00Outperform
    Mizuho
    1/23/2025$60.00Overweight
    Barclays
    6/28/2024$36.00Neutral → Buy
    Guggenheim
    6/3/2024$32.00Buy
    Jefferies
    4/24/2024$28.00Buy
    Craig Hallum
    12/14/2023Neutral
    Guggenheim
    12/13/2023Peer Perform
    Wolfe Research
    11/13/2023$27.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $GH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Guardant Health to Participate in Upcoming Investor Conferences

      Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BofA Securities 2025 Healthcare Conference in Las Vegas, NV Fireside chat on Wednesday, May 14th at 3:40 p.m. Pacific Time Jefferies Global Healthcare Conference in New York, NY Fireside chat on Wednesday, June 4th at 2:35 p.m. Eastern Time Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL Fireside chat on Monday, June 9th at 10:00 a.m. Eastern Time Interested parties may access live and archived webcasts of the sessions on the "Investors" section of the company website at: www.guardanthealth.com.

      5/8/25 4:05:00 PM ET
      $GH
      Medical Specialities
      Health Care
    • TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year

      Today TIME named to its 2025 TIME100 Health list co-CEOs Helmy Eltoukhy and AmirAli Talasaz of Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company. The list recognizes and honors the top 100 most influential people in global health this year. "The inclusion on TIME100 Health's list is more than a personal honor," said AmirAli Talasaz, Guardant Health co-CEO. "It is a recognition of the incredible technology that our Guardant team has built with the Shield blood test for colorectal cancer and Shield's ability to save lives around the world. The result of over 10 years of research and development, the Shield blood test has the promise to detect multiple cancers at an earl

      5/8/25 9:20:00 AM ET
      $GH
      Medical Specialities
      Health Care
    • Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that on April 22, 2025, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units ("RSUs") representing 157,466 shares of its common stock to 139 new non-executive employees and two non-qualified stock option awards to purchase 19,295 shares of its common stock to two new non-executive employees with a grant date of May 2, 2025 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"). The RSUs and stock options were granted as inducements material to the employees entering into employment with Guardant in ac

      5/7/25 5:05:00 PM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    SEC Filings

    See more
    • SEC Form 10-Q filed by Guardant Health Inc.

      10-Q - Guardant Health, Inc. (0001576280) (Filer)

      4/30/25 5:10:41 PM ET
      $GH
      Medical Specialities
      Health Care
    • Guardant Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Guardant Health, Inc. (0001576280) (Filer)

      4/30/25 4:11:06 PM ET
      $GH
      Medical Specialities
      Health Care
    • SEC Form DEFA14A filed by Guardant Health Inc.

      DEFA14A - Guardant Health, Inc. (0001576280) (Filer)

      4/29/25 4:35:16 PM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Guardant Health Inc.

      SC 13G - Guardant Health, Inc. (0001576280) (Subject)

      11/13/24 7:34:17 PM ET
      $GH
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Guardant Health Inc.

      SC 13G - Guardant Health, Inc. (0001576280) (Subject)

      11/8/24 10:46:38 AM ET
      $GH
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Guardant Health Inc.

      SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)

      7/5/24 10:32:48 AM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 30, 2024 - FDA Roundup: July 30, 2024

      For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

      7/30/24 3:38:18 PM ET
      $GH
      Medical Specialities
      Health Care
    • May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

      For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

      5/28/21 1:05:48 PM ET
      $AMGN
      $GH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities
    • May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

      For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

      5/21/21 12:50:51 PM ET
      $JNJ
      $GH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities

    $GH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Joyce Meghan V. converted options into 66 shares, increasing direct ownership by 0.85% to 7,846 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      5/5/25 9:03:07 PM ET
      $GH
      Medical Specialities
      Health Care
    • Co-Chief Executive Officer Talasaz Amirali sold $5,936,572 worth of shares (120,716 units at $49.18), decreasing direct ownership by 5% to 2,188,740 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      5/5/25 9:02:01 PM ET
      $GH
      Medical Specialities
      Health Care
    • Director Krognes Steve E. converted options into 155 shares, increasing direct ownership by 1% to 10,837 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      5/1/25 4:56:43 PM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    Financials

    Live finance-specific insights

    See more
    • Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

      Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights For the three-month period ended March 31, 2025, as compared to the same period of 2024: Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of $150.6 million, an increase of 20%, and approximately 59,000 oncology tests, an increase of 25% Screening revenue of $5.7 milli

      4/30/25 4:05:00 PM ET
      $GH
      Medical Specialities
      Health Care
    • Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025

      Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Gua

      4/10/25 4:05:00 PM ET
      $GH
      Medical Specialities
      Health Care
    • Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

      Full year 2024 total revenue growth of 31% driven by strong clinical oncology volume growth, Guardant360 ASP tailwinds, and product upgrades Expects full year 2025 total revenue to be in the range of $850 to $860 million Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights For the three-month period ended December 31, 2024, as compared to the same period of 2023: Total revenue of $201.8 million, an increase of 30% Reported approximately 57,300 oncology clinical tests (excluding Shield) and approximately 11,050 biopharma tests, an increa

      2/20/25 4:05:00 PM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $GH
    Leadership Updates

    Live Leadership Updates

    See more
    • Kalia Kumud bought $38,963 worth of shares (2,187 units at $17.82), increasing direct ownership by 21% to 12,722 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      3/19/24 5:29:06 PM ET
      $GH
      Medical Specialities
      Health Care
    • Guardant Health Joins Forces With Dak Prescott's Faith Fight Finish Foundation and Feist-Weiller Cancer Center's Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

      Foundation's grant to mobile cancer screening program in Louisiana allows individuals to be screened with Guardant's Shield™ blood test in their own community Mobile screening events to be held during Colorectal Cancer Awareness Month (March) throughout northern and central Louisiana Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a collaboration with Dak Prescott's Faith Fight Finish Foundation and the mobile cancer screening program, Partners in Wellness, an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center, to increase colorectal cancer screening rates in northern and central Louisiana. This press release

      3/5/25 8:05:00 AM ET
      $GH
      Medical Specialities
      Health Care
    • Roberto A. Mignone Joins Guardant Health Board of Directors

      Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look

      10/24/24 5:05:00 PM ET
      $GH
      Medical Specialities
      Health Care
    • Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors

      Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. "Dr. Hidalgo brings a wealth of expertise and leadership in translational and clinical research, particularly in anticancer drug development," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "His extensive experience in precision oncology and his commitment to advancing oncology care make him an invaluable addition to our board." A

      7/18/24 5:00:00 PM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Guardant Health with a new price target

      Mizuho initiated coverage of Guardant Health with a rating of Outperform and set a new price target of $55.00

      4/10/25 12:41:47 PM ET
      $GH
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Guardant Health with a new price target

      Barclays initiated coverage of Guardant Health with a rating of Overweight and set a new price target of $60.00

      1/23/25 7:45:30 AM ET
      $GH
      Medical Specialities
      Health Care
    • Guardant Health upgraded by Guggenheim with a new price target

      Guggenheim upgraded Guardant Health from Neutral to Buy and set a new price target of $36.00

      6/28/24 7:41:07 AM ET
      $GH
      Medical Specialities
      Health Care